StockData
60 Degrees Pharmaceuticals, Inc. logo

60 Degrees Pharmaceuticals, Inc. (SXTP) shareholders

SXTPNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTPW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3060% below fair value
$0.53+0.04 (+8.14%)

Close on Nov 17, 2026Market cap $1.88MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0M
Shares held, 13F filers
Institutional holders
8
3 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $30.09K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Knight Therapeutics International S.A.
Joint filing with Knight Therapeutics Inc. (9.97%)
1,153,8979.97%13G (passive) amendmentMar 31, 2024
Knight Therapeutics Inc.658,62919.85%13G (passive)Jul 22, 2026
Armistice Capital, LLC
Joint filing with Steven Boyd (9.99%)
476,8669.99%13G (passive) amendmentDec 31, 2024
CVI Investments, Inc.
Joint filing with Heights Capital Management, Inc. (9.90%)
455,5459.90%13G (passive) amendmentSep 30, 2025
Daniel B. Asher
Joint filing with Mitchell P. Kopin (9.99%), Intracoastal Capital LLC (9.99%)
390,3429.99%13G (passive) amendmentSep 30, 2026
Mitchell P. Kopin
Joint filing with Daniel B. Asher (9.99%), Intracoastal Capital LLC (9.99%)
372,4299.99%13G (passive)Jul 15, 2025
Intracoastal Capital LLC
Joint filing with Mitchell P. Kopin (9.10%), Daniel B. Asher (9.10%)
263,1589.10%13G (passive) amendmentMar 31, 2026
Heights Capital Management, Inc.
Joint filing with CVI Investments, Inc. (7.00%)
197,9117.00%13G (passive) amendmentMar 31, 2026
Lind Global Fund III LP
Joint filing with Lind Global Partners III LLC (5.45%), Easton Jeff (5.45%)
191,5715.45%13G (passive)Jul 31, 2026
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
Joint filing with Ayrton Capital LLC (9.99%), Waqas Khatri (9.99%)
163,4809.99%13G (passive)Mar 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SXTPValueChange% of portfolio
Kathmere Capital Management, LLC265,100–$466.58K+120,4170.02%
Citadel Advisors LLC22,362–$39.36KNew0.00%
XTX Topco Ltd17,639–$31.05KNew0.00%
Kovack Advisors, Inc.15,000–$26.40KNew0.00%
Geode Capital Management, LLC14,551–$25.61K−1,7440.00%
UBS Group AG13,592–$23.92K−17,8180.00%
Barclays PLC1,052–$1.85K−8040.00%
Osaic Holdings, Inc.25–$44–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 202680M3 / 13 / 30M0M
Q1 202680M8 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

FundShares% of SXTPValue% of fundAs of
Fidelity Extended Market Index Fund11,788–$17.56K0.00%May 31, 2026
Blackstone Alternative Multi-Strategy Fund-300–-$528-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Geoffrey S. DowPresident and CEO, Director35,250Jun 15, 2026
Kristen LandonChief Operating Officer4,540Aug 14, 2025
Tyrone MillerCFO26,370Jan 24, 2025
Eric FrancoisDirector–May 19, 2026
Cheryl XuDirector13,816Jun 5, 2025
Therapeutics Inc. Knight10% owner1,766,966Jul 29, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Geoffrey S. Dow
President and CEO, Director
Jun 12, 2026Buy+7,350$1.38$10.14K24,131
Geoffrey S. Dow
President and CEO, Director
Dec 15, 2025Buy+9,670$0.80$7.74K59,618
Geoffrey S. Dow
President and CEO, Director
Dec 11, 2025Buy+3,613$0.92$3.32K49,948
Geoffrey S. Dow
President and CEO, Director
Dec 10, 2025Buy+9,350$0.95$8.88K46,335
Geoffrey S. Dow
President and CEO, Director
Sep 12, 2025Award+7,201$1.39$10.01K33,372
Geoffrey S. Dow
President and CEO, Director
Jun 9, 2025Award+4,376$2.99$13.08K26,171
Cheryl Xu
Director
Jun 3, 2025Buy+3,000$2.87$8.61K13,816
Cheryl Xu
Director
Jun 3, 2025Buy+2,000$2.90$5.80K15,816
Kristen Landon
Chief Operating Officer
Jan 17, 2025Award+4,540––4,540
Tyrone Miller
CFO
Jan 17, 2025Award+11,626––26,370
Geoffrey S. Dow
President and CEO, Director
Jan 17, 2025Award+14,394––108,974
Cheryl Xu
Director
Dec 16, 2024Buy+2,000$1.45$2.90K54,078
Cheryl Xu
Director
Dec 13, 2024Buy+1,500$1.60$2.40K47,578
Cheryl Xu
Director
Dec 13, 2024Buy+1,500$1.58$2.37K49,078
Cheryl Xu
Director
Dec 13, 2024Buy+1,500$1.55$2.33K50,578
Cheryl Xu
Director
Dec 13, 2024Buy+1,500$1.52$2.28K52,078
Cheryl Xu
Director
Dec 12, 2024Buy+2,500$1.80$4.50K46,078
Cheryl Xu
Director
Dec 12, 2024Buy+2,500$1.85$4.63K43,578
Geoffrey S. Dow
President and CEO, Director
Dec 9, 2024Buy+35,823$1.27$45.50K94,580
Geoffrey S. Dow
President and CEO, Director
Dec 6, 2024Buy+20,579$1.20$24.69K58,757
Geoffrey S. Dow
President and CEO, Director
Dec 5, 2024Buy+17,549$1.11$19.48K38,178
Geoffrey S. Dow
President and CEO, Director
Nov 21, 2024Buy+3,500$0.91$3.19K20,629
Geoffrey S. Dow
President and CEO, Director
Nov 20, 2024Buy+1,000$0.92$92017,129
Geoffrey S. Dow
President and CEO, Director
Nov 19, 2024Buy+2,500$0.90$2.25K16,129
Cheryl Xu
Director
Aug 27, 2024Buy+5,000$1.70$8.50K41,078
Stephen Toovey
Director
May 16, 2024Award+4,000$0.22$88014,000
Geoffrey S. Dow
President and CEO, Director
May 16, 2024Option exercise+17,000$0.22$3.74K762,625
Charles W. Allen
Director
May 16, 2024Option exercise+4,000$0.22$88014,000
Paul Field
Director
May 16, 2024Option exercise+4,000$0.22$88014,000
Cheryl Xu
Director
May 16, 2024Option exercise+2,000$0.22$440228,934
Tyrone Miller
CFO
May 16, 2024Award+15,000$0.22$3.30K176,928
Geoffrey S. Dow
President and CEO, Director
Apr 12, 2024Option exercise+68,000$0.27$18.36K745,625
Tyrone Miller
CFO
Apr 12, 2024Award+60,000$0.27$16.20K161,928
Cheryl Xu
Director
Feb 1, 2024Option exercise+2,000––6,000
Geoffrey S. Dow
President and CEO, Director
Jan 31, 2024Buy+25,974$0.38$9.87K703,599
Cheryl Xu
Director
Jan 31, 2024Buy+200,000$0.38$76.00K424,934
Therapeutics International Sa Knight
–
Jul 28, 2023Conversion+45,560$4.75$216.41K1,153,897
Therapeutics International Sa Knight
–
Jul 28, 2023Conversion−2,162––78,803

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 2M shares a day
Change since last report
+88.4%
From 0M shares
Short volume, 20 days
45.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of 60 Degrees Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 62,960 shares on Aug 27, 2026 over the last 90 days.

See a number that looks wrong?